The project is delivering validated generalised model of significant and actionable factors affecting non-adherent behaviour. Disease-agnostic in nature, the model will help the project team to define the problem of non-adherence and provide guidance for health & care stakeholders as they develop and implement cost-effective digital tools and solutions. Interested in discovering how this model could contribute to better patient outcomes and reduced health system expenses? Keep on reading below!

What To Expect?

The BEAMER model:

  • Helps to build solutions that enable healthcare stakeholders to provide personalised patient support and improve adherence behaviour
  • Provides outcomes that enable healthcare stakeholders to develop products and services that are better aligned with patient needs and limitations

BEAMER will not design solutions or implement those that are stand-alone and patient-facing. Neither will it model HCPs’ behaviour nor validate interventions.

How It Works?

Who to Define Success?


When we can use this behavioural model to understand patient needs and improve adherence with personalized support options, the BEAMER project will achieve its goals.

Supported by a grant from IMI, the project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034369. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme, the European Federation of Pharmaceutical Industries and Associations [EFPIA] and Link2Trials. The total budget is 11.9 M€ for a project duration of 60 months.

Information on this website reflects project owner’s views and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.

Who’s Behind BEAMER
Subscribe to Newsletter
Press Office

Privacy Policy and Cookies

Follow us: